BR112015017246A8 - composição farmacêutica aquosa, seu uso e seringa - Google Patents

composição farmacêutica aquosa, seu uso e seringa Download PDF

Info

Publication number
BR112015017246A8
BR112015017246A8 BR112015017246A BR112015017246A BR112015017246A8 BR 112015017246 A8 BR112015017246 A8 BR 112015017246A8 BR 112015017246 A BR112015017246 A BR 112015017246A BR 112015017246 A BR112015017246 A BR 112015017246A BR 112015017246 A8 BR112015017246 A8 BR 112015017246A8
Authority
BR
Brazil
Prior art keywords
corticosteroid
injection
pharmaceutical composition
aqueous pharmaceutical
syringe
Prior art date
Application number
BR112015017246A
Other languages
English (en)
Other versions
BR112015017246A2 (pt
BR112015017246B1 (pt
Inventor
G Shah Mahendra
Original Assignee
Semnur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semnur Pharmaceuticals Inc filed Critical Semnur Pharmaceuticals Inc
Publication of BR112015017246A2 publication Critical patent/BR112015017246A2/pt
Publication of BR112015017246A8 publication Critical patent/BR112015017246A8/pt
Publication of BR112015017246B1 publication Critical patent/BR112015017246B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo patente de invenção: "formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel". são divulgadas composições farmacêuticas aquosas que fornecem distribuição com liberação prolongada de compostos corticosteroides. a composição farmacêutica compreende um corticosteroide insolúvel; um corticosteroide solúvel; e pelo menos um agente para a melhoria da viscosidade. também são fornecidos processos para utilização das composições farmacêuticas em uma injeção epidural, um injeção intra-articular, uma injeção intra-lesional ou uma injeção intra-ocular.
BR112015017246-6A 2013-01-23 2014-01-23 Composição farmacêutica aquosa injetável, seu uso e seringa BR112015017246B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361755723P 2013-01-23 2013-01-23
US61/755,723 2013-01-23
US201361776617P 2013-03-11 2013-03-11
US61/776,617 2013-03-11
PCT/US2014/012824 WO2014116876A1 (en) 2013-01-23 2014-01-23 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid

Publications (3)

Publication Number Publication Date
BR112015017246A2 BR112015017246A2 (pt) 2017-07-11
BR112015017246A8 true BR112015017246A8 (pt) 2019-10-29
BR112015017246B1 BR112015017246B1 (pt) 2022-11-29

Family

ID=50097866

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017246-6A BR112015017246B1 (pt) 2013-01-23 2014-01-23 Composição farmacêutica aquosa injetável, seu uso e seringa

Country Status (14)

Country Link
US (4) US9833460B2 (pt)
EP (1) EP2948182B1 (pt)
JP (1) JP6215354B2 (pt)
KR (1) KR102055937B1 (pt)
CN (1) CN105073138B (pt)
AU (2) AU2014209346B2 (pt)
BR (1) BR112015017246B1 (pt)
CA (1) CA2897467C (pt)
HK (1) HK1218074A1 (pt)
IL (1) IL239791B (pt)
MX (1) MX366654B (pt)
NZ (1) NZ709620A (pt)
TW (1) TWI624262B (pt)
WO (1) WO2014116876A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5042215B2 (ja) 2005-05-26 2012-10-03 ニューロン システムズ， インコーポレイテッド 網膜疾患を処置するための組成物および方法
MX366654B (es) 2013-01-23 2019-07-17 Semnur Pharmaceuticals Inc Formulación farmacéutica.
TW202245791A (zh) * 2015-01-21 2022-12-01 美商桑紐爾製藥公司 醫藥配方
AU2016269848B2 (en) * 2015-06-02 2021-12-09 Intravital Pty Ltd Formulation and process for limiting nerve trauma
EP3337486B1 (en) 2015-08-21 2024-04-03 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
EP3694500A4 (en) 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
WO2020118045A1 (en) * 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Injectable formulations
US11382863B2 (en) * 2020-03-04 2022-07-12 Somerset Therapeutics Llc Injectable suspension comprising an insoluble corticosteroid and a soluble corticosteroid
KR20230073269A (ko) * 2020-10-22 2023-05-25 화이자 인코포레이티드 코르티코스테로이드의 비경구 투여를 위한 peg-무함유 수성 현탁액

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25251A (en) 1965-07-20 1969-11-12 Merck & Co Inc Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
FI105075B (fi) 1996-01-10 2000-06-15 Suprakort Oy Kombinaatioinjektiovalmisteen käyttö
IT1288290B1 (it) 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
JPH11279065A (ja) 1998-03-25 1999-10-12 Shiseido Co Ltd 局所投与炎症治療剤
US6921532B1 (en) 2000-06-22 2005-07-26 Spinal Restoration, Inc. Biological Bioadhesive composition and methods of preparation and use
US6747090B2 (en) * 2001-07-16 2004-06-08 Pharmacia Groningen Bv Compositions capable of forming hydrogels in the eye
US20040006052A1 (en) 2002-04-15 2004-01-08 Gudas Charles J. Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050186229A1 (en) 2004-02-24 2005-08-25 Emmett Clemente Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate
JP2007001926A (ja) * 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
JP4969812B2 (ja) 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
US20070099882A1 (en) 2005-10-27 2007-05-03 Gurney Harry C Methods and compositions for prolonged alleviation of articular joint pain
EP1968614A2 (en) 2005-12-14 2008-09-17 Anika Therapeutics Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
CN100534434C (zh) * 2006-05-15 2009-09-02 西安力邦制药有限公司 透明质酸钠***脂肪乳制剂及其应用
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9421356B2 (en) * 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090143807A1 (en) 2007-12-03 2009-06-04 Vertos Medical, Inc., A Delaware Corporation Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same
BRPI0905078A2 (pt) 2008-04-18 2015-06-30 Medtronic Inc Métodos para tratar hérnia de disco intervertebral e para reduzir o tamanho de uma hérnia de disco intervertebral, e, depósito implantável de drogas
MY161021A (en) * 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
EP2365812A4 (en) * 2008-11-10 2012-05-16 Nitric Biotherapeutics Inc PHARMACEUTICAL FORMULATIONS FOR THE IONTOPHORETIC DELIVERY OF A CORTICOSTEROID
AU2010276574B2 (en) * 2009-07-30 2015-08-20 Carbylan Therapeutics, Inc. Modified hyaluronic acid polymer compositions and related methods
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2459615C1 (ru) 2011-03-05 2012-08-27 Илья Александрович Марков Глазные капли для лечения болезни сухого глаза
MX2014006056A (es) 2011-12-06 2014-08-08 Alcon Res Ltd Composicion de gel de celulosa con una mejor estabilidad de la viscosidad.
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
MX366654B (es) 2013-01-23 2019-07-17 Semnur Pharmaceuticals Inc Formulación farmacéutica.
TW202245791A (zh) 2015-01-21 2022-12-01 美商桑紐爾製藥公司 醫藥配方

Also Published As

Publication number Publication date
CA2897467A1 (en) 2014-07-31
BR112015017246A2 (pt) 2017-07-11
US11364251B2 (en) 2022-06-21
CN105073138B (zh) 2018-06-05
US20210052605A1 (en) 2021-02-25
AU2014209346A1 (en) 2015-07-23
EP2948182B1 (en) 2020-09-30
US20140356434A1 (en) 2014-12-04
CA2897467C (en) 2020-09-22
BR112015017246B1 (pt) 2022-11-29
AU2019200649B2 (en) 2020-02-27
WO2014116876A8 (en) 2015-08-20
AU2019200649A1 (en) 2019-02-21
MX366654B (es) 2019-07-17
IL239791A0 (en) 2015-08-31
AU2014209346B2 (en) 2018-11-15
TWI624262B (zh) 2018-05-21
EP2948182A1 (en) 2015-12-02
US20180235980A1 (en) 2018-08-23
US9833460B2 (en) 2017-12-05
CN105073138A (zh) 2015-11-18
JP2016510329A (ja) 2016-04-07
KR20150114505A (ko) 2015-10-12
HK1218074A1 (zh) 2017-02-03
NZ709620A (en) 2020-07-31
KR102055937B1 (ko) 2019-12-13
JP6215354B2 (ja) 2017-10-18
MX2015009455A (es) 2016-01-12
WO2014116876A1 (en) 2014-07-31
IL239791B (en) 2020-11-30
TW201442713A (zh) 2014-11-16
US20220370476A1 (en) 2022-11-24
US10744144B2 (en) 2020-08-18

Similar Documents

Publication Publication Date Title
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
BR112018074450A2 (pt) composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
BR112017026746A2 (pt) composições de liberação de fármacos implantáveis e métodos de uso dos mesmos
BR112016001544A2 (pt) composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
BR112018013979A2 (pt) composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
MX2021012029A (es) Composicion farmaceutica de corticosteroide soluble.
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
BR112013001462B8 (pt) Composições
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
MX2019014666A (es) Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo.
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112018007399A2 (pt) composição, método de tratamento, kit de partes e forma de dosagem
BRPI0815280A2 (pt) medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25G Requested change of headquarter approved

Owner name: SEMNUR PHARMACEUTICALS, INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/01/2014, OBSERVADAS AS CONDICOES LEGAIS